Atlas Trials

A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

Clinical trial NCT07145918 · RECRUITING

Trial details

NCT number
NCT07145918
Sponsor
AbbVie
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Schizophrenia
Start date
2025-08-04
Primary completion
2028-02-01
Enrollment
268

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.